Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Trading Performance

Ulcer Index



Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 9 49.8 0.78% 1.40% 7.1% -0.9% 45.4%
SHORT 7 39.0 0.71% 1.67% 56.1% -2.2% 274.1%


Technical Analysis

Bionomics (BNO.AX)



Last Signal:


Trading: BUY @ $0.135
Signal Strength: MEDIUM

Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.

Bionomics (ASX:BNO) UIX index implies that the downside risk of the current trading price is high. Currently, the UIX is 7.946.

A technical indicator that measures downside risk in terms of both depth and duration of price declines. The Ulcer Index (UI) increases in value as the price moves farther away from a recent high and falls as the price rises to new highs. The indicator is usually calculated over 14 days with the UI showing the percentage drawdown a trader can expect from the high over that period. The greater the value of the UI the longer it takes for a stock to get back to the former high.

Calculation: Ulcer Index:
1) Percentage Drawdown = [(Close - 14-period High Close)/14-period High Close] x 100;
2) Squared Average = (14-period Sum of Percentage Drawdown Squared)/14;
3) Ulcer Index = Square Root of Squared Average;

PROFILE: Bionomics (BNO.AX)

Stock Exchange: ASX
Company: Bionomics
Ticker Codes: | BNO.AX | ASX:BNO |

About Bionomics (ASX:BNO):

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in the initiation of a Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has partnerships with Merck & Co., Inc.; Cancer Therapeutics Cooperative Research Centre; Genmab A/S; Laboratory Corporation of America (LabCorp); Athena Diagnostics; and Genetic Technologies Limited. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.

Top 10:

Ulcer Index

Company Close Change(%) Volume Value Signal
NHF NIB 6.82 15.8 4,054,736 6.06 BEARISH
GNG GR Engineering Services 0.95 9.8 41,600 7.95 BEARISH
EML Emerchants 2.25 9.2 1,361,616 7.97 BEARISH
WBC Westpac Banking Corporation 27.75 9.2 24,404,464 5.77 BEARISH
ALK Alkane Exploration 0.24 9.1 1,447,163 8.27 BEARISH
AHG Advance Healthcare 2.55 9 1,585,387 6.2 BEARISH
OVH Onevue Holdings 0.49 8.9 426,122 7.89 BEARISH
RHC Ramsay Health Care 69.58 7.3 1,172,273 9.74 BEARISH
AYS Amaysim Australia 0.76 7 283,622 7.58 BEARISH
CBA Commonwealth Bank 77.4 6.3 9,829,411 7.04 BEARISH